The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 597.82% and ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Rhythm Pharmaceuticals (RYTM) stock gains as JMP Securities issues a positive view on the company citing its lead product ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...